Sign in Subscribe
Pharmaceutical industry

Global Chronic Kidney Disease (CKD) Drugs Market Size to Reach $15.5 Billion by 2026

Strategic Insights

— 2 min read

The global Chronic Kidney Disease (CKD) drugs market is projected to grow significantly, driven by the increasing prevalence of CKD and the launch of new drugs. Amid the COVID-19 crisis, the market is estimated to reach $15.5 billion by 2026, growing at a CAGR of 1.9% over the analysis period. The report by Global Industry Analysts Inc. presents fresh perspectives on opportunities and challenges in a significantly transformed post-COVID-19 marketplace.

Key Takeaways:

  • The global CKD drugs market is estimated at $13.7 billion in 2020 and is projected to reach $15.5 billion by 2026, growing at a CAGR of 1.9% over the analysis period.
  • The market is driven by the increasing prevalence of CKD, the launch of new drugs, and the growing demand for healthcare services.
  • The Calcium Channel Blockers segment is projected to record a 1.8% CAGR and reach $3.4 billion by the end of the analysis period.
  • The Antihypertensives segment is readjusted to a revised 1.9% CAGR for the next 7-year period, driven by the increasing prevalence of hypertension and the growing demand for antihypertensive medications.
  • The U.S. market is estimated at $3.8 billion in 2021, while China is forecast to reach $2.9 billion by 2026, growing at a CAGR of 3.6% over the analysis period.
  • The Erythropoiesis-Stimulating Agents (ESAs) segment is projected to reach $2.4 billion by 2026, driven by the increasing prevalence of anemia and the growing demand for ESAs.

Sources:

  • Global Industry Analysts Inc., (GIA), 2021, "Chronic Kidney Disease (CKD) Drugs - Global Market Trajectory & Analytics"
  • Global Industry Analysts Inc., (GIA), 2021, "FACTS AT A GLANCE" Edition: 9

Statistics:

  • The global CKD drugs market is estimated at $13.7 billion in 2020.
  • The market is projected to reach $15.5 billion by 2026, growing at a CAGR of 1.9% over the analysis period.
  • The Calcium Channel Blockers segment is projected to record a 1.8% CAGR and reach $3.4 billion by the end of the analysis period.
  • The Antihypertensives segment is readjusted to a revised 1.9% CAGR for the next 7-year period.
  • The U.S. market is estimated at $3.8 billion in 2021.
  • China is forecast to reach $2.9 billion by 2026, growing at a CAGR of 3.6% over the analysis period.
  • The Erythropoiesis-Stimulating Agents (ESAs) segment is projected to reach $2.4 billion by 2026.

**Note:** All statistics are based on the data provided in the source material and may not reflect the actual market size or growth rate.

Read more